Apogee Therapeutics (APGE)

$

9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
.
9
8
7
6
5
4
3
2
1
0
0
-$0.36 (-0.73%)Past DayToday's Volume:
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
,
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0

Relative Strength Index (RSI)

- The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. It is typically used to identify overbought or oversold conditions in financial markets.

- The RSI is calculated using the following formula:

RSI = 100 - (100 / (1 + RS))

Where RS is the ratio of the average gains to the average losses over a specified period.

- The default time period used is 14 days.

- RSI values range between 0 and 100.

RSI values above 70 are considered overbought (indicating a potentially opportune time to sell)

RSI values below 30 are considered oversold (indicating a potentially opportune time to buy)

RSI is not a perfect indicator and should be used in conjunction with other technical analysis tools, this is for informational purposes only and is not a substitute for professional financial advice.

About

Business overview of Apogee Therapeutics (APGE)
Apogee Therapeutics Inc is a biotechnology company seeking to develop differentiated biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD) and related inflammatory and immunology (I&I) indications with high unmet need. Its antibody programs are designed to overcome the limitations of existing therapies by targeting well-established mechanisms of action and incorporating advanced antibody engineering to optimize half-life and other properties. Its two programs are APG777 and APG808, which initially develop for treating AD and COPD, respectively.

Key Insights

Critical company metrics and information

  • Share Price

    $48.61

  • Market Cap

    $2.77 Billion

  • Total Outstanding Shares

    45.03 Million Shares

  • Total Employees

    91

  • Dividend

    No dividend

  • IPO Date

    July 14, 2023

  • SIC Description

    Biological Products, (no Disgnostic Substances)

  • Primary Exchange

    NASDAQ

  • Type

    Common Stock

  • Phone Number

    650-394-5230

  • Address

    221 crescent st., Waltham, MA, 02453

  • Homepage

    https://www.apogeetherapeutics.com

Historical Stock Splits

If you bought 1 share of APGE before January 8, 2008, you'd have 0.02 shares today.
Execution DateSplit Amount
January 8, 20081-for-50 (Reverse Split)

Cash Flow Statement

July 1, 2024 to September 30, 2024
MetricValue
Net Cash Flow From Investing Activities$-146.38 Million
Net Cash Flow, Continuing$-188.52 Million
Net Cash Flow From Financing Activities$383,000.00
Net Cash Flow From Investing Activities, Continuing$-146.38 Million
Net Cash Flow From Operating Activities, Continuing$-42.52 Million
Net Cash Flow From Financing Activities, Continuing$383,000.00

Income Statement

July 1, 2024 to September 30, 2024
MetricValue
Income/Loss From Continuing Operations After Tax$-49.02 Million
Net Income/Loss Attributable To Noncontrolling Interest$0.00
Other Operating Expenses$12.97 Million
Basic Earnings Per Share$-0.86
Basic Average Shares$56.80 Million
Operating Income/Loss$-58.69 Million

Balance Sheet

July 1, 2024 to September 30, 2024
MetricValue
Assets$776.29 Million
Prepaid Expenses$3.27 Million
Equity Attributable To Noncontrolling Interest$0.00
Current Assets$534.48 Million
Other Current Liabilities$23.48 Million
Equity$734.40 Million

Historical Dividends

Announcement DatePayment DateRecord DateAmountFrequency
No historical dividends
Boost your savings and earn 4.35% APY with a Marcus by Goldman Sachs savings account, a rate that's 8x the national averagewhen signing up with Financhle. No fees, no minimum deposits, backed by the financial expertise of Goldman Sachs. Terms apply.
Earnings CalendarNews ArticlesAbout UsPrivacy & Cookies Info

ⓒ 2025 Financhle. All Rights Reserved.